Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Total number of voting rights and shares - Dec 2024

  • Read more about Total number of voting rights and shares - Dec 2024

New transparency notifications - 23 January 2025

  • Read more about New transparency notifications - 23 January 2025

New Transparency Notification

Medsenic, filiale de BioSenic, signe une lettre d'intention conditionnelle qui pourrait sécuriser la prise en charge d'une partie des frais de son essai clinique sur la maladie chronique du greffon contre l'hôte

  • Read more about Medsenic, filiale de BioSenic, signe une lettre d'intention conditionnelle qui pourrait sécuriser la prise en charge d'une partie des frais de son essai clinique sur la maladie chronique du greffon contre l'hôte

Mont-Saint-Guibert, Belgique, le 13 décembre 2024, 17h30 – BIOSENIC (Euronext Bruxelles et Paris : BIOS) annonce la signature d'une lettre d’intention conditionnelle entre Medsenic SAS et la société basée à Singapour TrialCap Pte. Ltd. constituant une première étape pour une proposition de financement par emprunt et par souscription d'actions.

Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft-versus-host disease

  • Read more about Medsenic, a subsidiary of BioSenic, has signed a conditional letter of intent that could secure funding to cover part of the costs for its clinical trial on chronic graft-versus-host disease

Mont-Saint-Guibert, Belgium, 13 December 2024, 17:30 CET – BIOSENIC (Euronext Brussels and Paris : BIOS) announces the signing of a conditional letter of intent between Medsenic SAS and the Singapore based TrialCap Pte. Ltd. as a first step for a proposed financing arrangement through both debt and equity subscription.

Carole Nicco se retire de ses fonctions de Directrice Scientifique et des Opérations de BioSenic afin de se focaliser sur la filiale Medsenic SAS

  • Read more about Carole Nicco se retire de ses fonctions de Directrice Scientifique et des Opérations de BioSenic afin de se focaliser sur la filiale Medsenic SAS

Carole Nicco steps down from her roles as Chief Scientific and Operations Officer of BioSenic to focus on the subsidiary Medsenic SAS

  • Read more about Carole Nicco steps down from her roles as Chief Scientific and Operations Officer of BioSenic to focus on the subsidiary Medsenic SAS

Notification de transparence reçue de la part de ABO Infinium Americas OpCo LTD.

  • Read more about Notification de transparence reçue de la part de ABO Infinium Americas OpCo LTD.

Transparency notification received from ABO Infinium Americas OpCo LTD.

  • Read more about Transparency notification received from ABO Infinium Americas OpCo LTD.

BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors

  • Read more about BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors

BioSenic annonce démarrer la recherche de nouveaux actifs, la sécurisation de son financement pour les prochains mois par le biais d'un avenant à son contrat d'obligations convertibles, une modification de la composition de son conseil

  • Read more about BioSenic annonce démarrer la recherche de nouveaux actifs, la sécurisation de son financement pour les prochains mois par le biais d'un avenant à son contrat d'obligations convertibles, une modification de la composition de son conseil

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions